1. >
  2. Investors
  3. >
  4. Regulated Information
  5. >
  6. Press Releases – Reg...

PRESS RELEASES

Found 284 Results
Page 1 of 29

Onxeo Reports its 2021 Half-Yearly Financial Results and Provides an Update on its Activities


Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]

07/29/2021


Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board


Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee   […]

Tags:


Onxeo: Report on the Combined General Meeting of June 10, 2021


All resolutions voted in accordance with Board of Directors’ recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]

06/10/2021


Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States


This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]

06/09/2021


Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts


This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of […]

05/31/2021


Onxeo’s Combined General Meeting on June 10, 2021 in camera: availability of preparatory documents and live webcast login information


Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

05/21/2021


Publication of the 2020 Annual Financial Report


Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]

Tags:

04/23/2021


Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update


Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]

04/21/2021


Onxeo announces the success of its Rights Issue with €9.7 million raised


This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]

04/12/2021


Onxeo to Present New Preclinical Data at AACR 2021


Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]

Tags: ,

04/08/2021


Page 1 of 29